T. Rowe Price Associates
LXEO icon

T. Rowe Price Associates’s Lexeo Therapeutics LXEO Stock Holding History

T. Rowe Price Associates’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$271K Buy
58,194
+15,062
+35% +$81.5K ﹤0.01% 2888
2026
Q1 		$248K Buy
43,132
+9,260
+27% +$65.6K ﹤0.01% 2762
2025
Q4 		$337K Buy
33,872
+21,907
+183% +$200K ﹤0.01% 2590
2025
Q3 		$80K Buy
11,965
+1,540
+15% +$7.45K ﹤0.01% 2961
2025
Q2 		$42K Hold
10,425
– – ﹤0.01% 3017
2025
Q1 		$37K Hold
10,425
– – ﹤0.01% 2960
2024
Q4 		$69K Buy
+10,425
New +$82.1K ﹤0.01% 2891

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

T. Rowe Price Associates's LXEO Position: Q2 2026 in Review

T. Rowe Price Associates increased its Lexeo Therapeutics (LXEO) stake by 35% in Q2 2026, buying an estimated $81.5K and bringing the position to 58,194 shares worth $271K. The position accounts for ﹤0.01% of the portfolio, ranked #2888.

T. Rowe Price Associates first reported a position in LXEO in Q4 2024 and has held it in 7 quarters since. The position peaked at $337K in Q4 2025. 141 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • T. Rowe Price Associates held 58,194 shares of Lexeo Therapeutics worth $271K as of Q2 2026.
  • T. Rowe Price Associates bought 15,062 Lexeo Therapeutics shares in Q2 2026, an estimated $81.5K.
  • Lexeo Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2888 holding.
  • T. Rowe Price Associates first reported a position in Lexeo Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • T. Rowe Price Associates's Lexeo Therapeutics position peaked at $337K in Q4 2025.
  • 141 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.